Trading Report: Today, Insider Selling: Asterias Biotherapeutics Inc (AST) Insider Sold $14,069.80 in Stock

Today, Insider Selling: Asterias Biotherapeutics Inc (AST) Insider Sold $14,069.80 in Stock

Asterias Biotherapeutics Inc (NYSEMKT:AST) insider Edward Wirth sold 3,415 shares of Asterias Biotherapeutics stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $4.12, for a total transaction of $14,069.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Edward Wirth also recently made the following trade(s): On Friday, September 9th, Edward Wirth sold 14,760 shares of Asterias Biotherapeutics stock. The stock was sold at an average price of $3.52, for a total transaction of $51,955.20.

Asterias Biotherapeutics Inc (NYSEMKT:AST) opened at 3.82 on Monday. Asterias Biotherapeutics Inc has a 52 week low of $2.30 and a 52 week high of $5.75. The company’s market capitalization is $173.50 million. The stock’s 50 day moving average is $3.83 and its 200 day moving average is $3.49.

Asterias Biotherapeutics (NYSEMKT:AST) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.07. The firm earned $1.53 million during the quarter, compared to analysts’ expectations of $1.14 million. On average, equities research analysts expect that Asterias Biotherapeutics Inc will post ($0.73) earnings per share for the current year.

AST has been the subject of several recent research reports. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 19th. FBR & Co reissued a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, August 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Asterias Biotherapeutics in a research note on Sunday, September 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $7.75.

A number of institutional investors have recently bought and sold shares of the stock. Sabby Management LLC bought a new position in Asterias Biotherapeutics during the second quarter valued at $741,000. BlackRock Fund Advisors boosted its position in Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares during the last quarter. BlackRock Investment Management LLC boosted its position in Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock valued at $176,000 after buying an additional 36,782 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock valued at $131,000 after buying an additional 19,469 shares during the last quarter. Finally, State Street Corp boosted its position in Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock valued at $452,000 after buying an additional 5,000 shares during the last quarter.

Related posts

Leave a Comment